Results 291 to 300 of about 26,112,494 (338)

Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

Science, 1994
K. Grabstein, J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, Manfred Schoenborn, M. Ahdieh   +9 more
semanticscholar   +1 more source

Interleukin 2 see Dacarbazine/interleukin 2

Reactions Weekly, 1990
openaire   +1 more source

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Journal of Clinical Oncology, 1995
G. Fyfe, R. Fisher, S. Rosenberg, M. Sznol, D. Parkinson, A. Louie   +5 more
semanticscholar   +1 more source

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

Nature reviews. Immunology, 2006
T. Waldmann
semanticscholar   +1 more source

Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

Cell, 1992
R. Schwartz
semanticscholar   +1 more source

Interleukin-2

Reactions Weekly, 2016
Anand Rotte, Madhuri Bhandaru
openaire   +2 more sources

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Andrea Rubbert-Roth, César R Ramos-Remus, Rieke E Alten   +2 more
exaly  

Interleukin 2 see Iohexol/interleukin 2

Reactions Weekly, 1991
openaire   +1 more source

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

New England Journal of Medicine, 1987
W. West, K. Tauer, J. Yannelli, G. Marshall, D. Orr, G. Thurman, R. Oldham   +6 more
semanticscholar   +1 more source

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly